← Search & browse all drugs

glimepiride and dapagliflozin

A10BD32

Forms & Strengths

Fixed-dose combination tablet: Glimepiride 2 mg / Dapagliflozin 10 mg
Fixed-dose combination tablet: Glimepiride 4 mg / Dapagliflozin 10 mg

Adult Dosing

Type 2 diabetes mellitus: One tablet daily taken in the morning with or without food
Max daily dose: Glimepiride 4 mg / Dapagliflozin 10 mg daily
Renal impairment: Contraindicated if eGFR < 45 mL/min/1.73m²

Pediatric Dosing

Safety and efficacy not established in pediatric patients under 18 years of age

Indications

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both glimepiride and dapagliflozin is appropriate

Mechanism of Action

Glimepiride: Sulfonylurea that stimulates insulin release from pancreatic beta cells and reduces glucose output from the liver
Dapagliflozin: Sodium-glucose cotransporter 2 (SGLT2) inhibitor that inhibits renal reabsorption of glucose, increasing urinary glucose excretion and lowering blood glucose

Contraindications

Hypersensitivity to glimepiride, dapagliflozin, or sulfonamide derivatives
Type 1 diabetes mellitus or diabetic ketoacidosis
Severe renal impairment (eGFR < 45 mL/min/1.73m²), end-stage renal disease, or patients on dialysis

Adverse Reactions

Hypoglycemia
Female genital mycotic infections
Nasopharyngitis
Urinary tract infections
Back pain
Polyuria
Volume depletion and hypotension

Drug Interactions

Insulin or insulin secretagogues (e.g., sulfonylureas): Increased risk of severe hypoglycemia
CYP2C9 inhibitors/inducers: May alter glimepiride metabolism and plasma concentrations
Diuretics: Dapagliflozin may additive-enhance diuretic effect and increase risk of dehydration and hypotension
Lithium: SGLT2 inhibitors may increase renal lithium clearance, leading to decreased serum lithium concentrations

Curated Content: Needs Vetting Before Put to Clinical Use